INVESTIGADORES
VARGAS ROIG Laura Maria
congresos y reuniones científicas
Título:
APE1 expression in biopsies from breast cancer patients treated with anthracyclines neoadjuvant monochemotherapy
Autor/es:
GAUNA G.; NADIN S.B.; DAGUERRE, P.; LEUZZI, M.; GAGO, F.E.; IBARRA, J.; VARGAS ROIG, L.M.
Lugar:
San Juan
Reunión:
Congreso; 2da Reunión Conjunta de Sociedades de Biología de la República Argentina; 2011
Institución organizadora:
Sociedad de Biología de Cuyo
Resumen:
Doxorubicin (DOX) produces reactive oxygen species which damage DNA. This damage may be repaired by the Base Excision Repair system (BER). APE1 is a key enzyme in BER. Objectives: 1) to determine the APE1 expression before and after chemotherapy with DOX or epirubicin (EPI) and 2) to correlate APE1 with drug response and patient survival. Thirty-three patients received 75 mg/m2 of DOX or 120 mg/m2 of EPI, during 4 cycles before surgery, and 6 cycles with CMF after surgery. Nuclear expression of APE1 (evaluated by immunohistochemistry) increased after drug administration (p = 0,03). No correlation was found between nuclear/cytoplasmic APE1 expression with clinical/pathological response.
